Med Bull Sisli Etfal Hosp. 2022; 56(2): 189-195 | DOI: 10.14744/SEMB.2021.35902

Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit

Sultan Acar Sevinc¹, Ayse Surhan Cinar¹, Nermin Balta Basi¹, Seyhan Metin¹, Tugba Yucel¹, Serkan Islamoglu¹, Mustafa Altinay¹, Haci Mustafa Ozdemir^2
1Department of Anesthesiology and Reanimation, University of Health Sciences Turkey, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey
²Department of Orthopedics, University of Health Sciences Turkey, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey

Objectives: The aim of this study was to compare intensive care unit (ICU) and overall hospital mortality in patients treated with favipiravir and lopinavir-ritonavir for COVID-19.
Methods: Data were collected retrospectively between March 10 and May 10, 2020, from patients’ records admitted to ICU due to COVID-19. Laboratory data, clinical characteristics, ICU and hospital mortality, ICU and hospital length of stay were compared in patients treated with favipiravir and lopinavir-ritonavir.
Results: A total of 100 patients’ data were investigated. Favipiravir was used as the treatment for 85% of patients, with the rest treated with lopinavir-ritonavir. Clinical and laboratory data of both antiviral treatment groups were similar. Length of hospital stay was 16 (9–24) days with favipiravir and 8.5 (5–12.5) days with lopinavir-ritonavir (p=0.002). Length of ICU stay for favipiravir and lopinavir-ritonavir groups were 8 (5–15) days and 4 (3–9) days, respectively (p=0.011). ICU mortality was 65.9% for the favipiravir and 80% for lopinavir-ritonavir (p=0.002). Hospital mortality for favipiravir and lopinavir-ritonavir was 67.1% and 80%, respectively (p=0.001).
Conclusion: The mortality in patients treated with favipiravir was less than patients treated with lopinavir-ritonavir. Favipiravir needs more attention and trials for its effect to be confirmed.

Keywords: COVID-19, intensive care unit, favipiravir, lopinavir-ritonavir, mortality

---

Üçüncü düzey bir yoðun bakým ünitesindeki COVID-19’lu hastalarda favipiravir tecrübesi

Sultan Acar Sevinc¹, Ayse Surhan Cinar¹, Nermin Balta Basi¹, Seyhan Metin¹, Tugba Yucel¹, Serkan Islamoglu¹, Mustafa Altinay¹, Haci Mustafa Ozdemir^2
1Þiþli Hamidiye Etfal Eðitim ve Araþtýrma Hastanesi, Anesteziyoloji ve Reanimasyon Bölümü, Ýstanbul
²Saðlýk Bilimleri Üniversitesi, Þiþli Hamidiye Etfal Eðitim ve Araþtýrma Hastanesi, Ortopedi Anabilim Dalý, Ýstanbul

Amaç: COVID-19 nedeni ile Yoðun bakým ünitesinde (YBÜ) yatarak favipiravir ve lopinavir-ritonavir ile tedavi edilen hastalarda YBÜ ve hastane mortalitesinin karþýlaþtýrýlmasýdýr.
Metot: 10 Mart ve 10 Mayýs 2020 arasýnda YBÜ’ye yatan COVID-19’lu hastalarýn verileri geçmiþe yönelik toplanmýþtýr. Favipiravir ve lopinavir-ritonavir alan hastalar arasýnda laboratuvar verileri, klinik özellikler, YBÜ ve hastane mortalitesi, YBÜ ve hastanede kalýþ süresi karþýlaþtýrýlmýþtýr.
Bulgular: Toplam 100 hastanýn verisi incelenmiþtir. Hastalarýn %85’inde favipiravir, geri kalanýnda lopinavir-ritonavir kullanmýþtýr. Her iki grubun klinik ve laboratuvar verileri benzerdir. Favipiravir alan hastalarýn hastane yatýþ süresi 16 (9-24) gün iken lopinavir-ritonavir alanlarýnki 8.5 (5-12.5) gündür (p=0.002). YBÜ yatýþ süresi favipiravir ve lopinavir-ritonavir alan hastalarda sýrasý ile 8 (5-15) ve 4 (3-9) gündür (p=0.011). YBÜ mortalitesi favipiravir için %65.9, lopinavir-ritonavir için %80’dir (p=0.002). Hastane mortalitesi favipiravir ve lopinavir-ritonavir için sýrasý ile % 67.1 ve % 80’dir (p=0.001).
Sonuç: Favipiravir ile tedavi edilen hastalarýn mortalitesi lopinavir-ritonavir ile tedavi edilenlerden azdýr. Favipiravirin etkisinden emin olunabilmesi için daha fazla çalýþmaya ihtiyaç vardýr. (SETB-2021-07-212)

Anahtar Kelimeler: COVID-19, favipiravir, lopinavir-ritonavir, mortalite, yoðun bakým ünitesi

---

CITE